日本のCAR-T細胞治療市場は2032年までに大幅な成長を遂げる準備ができています
Dream News 2025年06月19日 09:30:00
Rising incidence of cancer across the globe is projected to primarily boost the demand for CAR-T cell therapy （Chimeric Antigen Receptor T-cell） therapy in the coming years. Increasing investments in cell research and advancements in genetic engineering and editing technologies are also expected to play a key role in the development of the CAR-T cell therapy market over the coming years. High demand for personalized medicine is also estimated to boost the demand for CAR-T cell therapy over the forecast period and beyond.
The CAR-T cell therapy market size is valued at USD 3.62 billion in 2023 and is poised to grow from USD 4.75 billion in 2024 to USD 41.78 billion by 2032, at a CAGR of 31.23% during the forecast period （2025-2032）.
Get Free Sample Report Now - https://www.skyquestt.com/sample-request/car-t-cell-therapy-market
Key Drivers of CAR-T Cell Therapy Market
● Increasing Prevalence of Cancer Globally - Rising incidence of various cancers is driving the adoption of innovative immunotherapies like CAR T-Cell therapy.
● Advances in Gene Editing and Cell Engineering - Technological advancements are improving the efficacy and safety profile of CAR-T Cell therapy.
● Expanding Regulatory Approvals and Clinical Trials - Increasing FDA and EMA approvals, as well as clinical trials globally, are fueling market growth.
● Growing Investments by Biopharmaceutical Companies - Large pharmaceutical and biotechnology companies are investing in research and development of next-generation CAR-T-Cell products.Market SegmentationThe
global
CAR-T cell therapy market is segmented by product, target, indication, demographics, end user, and region.
● Based on product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other products.
● Based on target, the market is segmented into CD19, BCMA, and Other targets.
● Based on indication, the market is segmented into multiple myeloma, B-cell lymphoma, acute lymphoblastic leukemia, and other indications.
● Based on demographics, the market is segmented into adult and pediatric.
● Based on end user, the market is segmented into hospitals, specialty centers, and long-term care facilities.
● Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East &Africa.
Regional Insights
North America is projected to hold a dominant share in the global CAR-T cell therapy market. High investments in medical research and development and growing acceptance of cell therapy among patients are projected to aid the high market share in this region.
The United States is estimated to be the most favorable market for CAR-T cell therapy companies owing to the presence of major CAR-T cell therapy providers. The potential for high healthcare costs and increasing availability of reimbursement for CAR-T cell therapy will also create new opportunities for CAR-T cell therapy providers in the future.
The Asia Pacific region is anticipated to emerge as the fastest-expanding CAR-T cell therapy market in the world in the coming years. Rapid growth in patient population, rising healthcare expenditure, and increasing demand for new treatments are estimated to bolster the demand for CAR-T cell therapy in the region.
China, Japan, and India are expected to emerge as the most favorable markets for all CAR-T cell therapy companies globally. Also, the presence of multiple contract research organizations and ease of regulatory approval procedures will play a key role in driving the demand for CAR-T cell therapy in the Asia-Pacific region in the coming years.
Challenges and Future
OpportunitiesChallenges:
● High cost of CAR-T cell therapy limiting accessibility
● Complex manufacturing and logistical requirements
● Potential for severe side effects such as cytokine release syndromeOpportunities
:
● Development of off-the-shelf （allogeneic） CAR-T cell therapy
● Application in the treatment of solid tumours other than hematological cancers
● Integration with advanced gene editing technologies such as CRISPRTop
Players in the CAR-T Cell Therapy Market
● Novartis AG （Switzerland）
● Johnson &Johnson （USA）
● JW （Cayman） Therapeutics Ltd. （Cayman Islands）
● Immunoadoptive Cell Therapy Private Limited （Immunoact） （India）
● Carsgen Therapeutics Holdings Limited （China）
● IASO Biotherapeutics （China）
● Guangzhou Bio-Gene Technology Co., Ltd （Hejing Group Co., Ltd） （China）
● Cartesian Therapeutics, Inc. （USA）
● Autolus Therapeutics （UK）
● Allogene Therapeutics （USA）
● Crispr Therapeutics （Switzerland）
● Ugen （USA）
● Sangamo Therapeutics, Inc. （USA）
● Bluebird Bio, Inc. （USA）
● TCR2 Therapeutics Inc. （USA）
● Genocea Biosciences, Inc. （USA）
● Blairex Laboratories, Inc. （USA）
● Medigene AG （Germany）
● Athenex, Inc. （USA）
● Zymeworks Inc. （Canada）
● Regenxbio Inc. （USA）
Recent Developments
● In April 2024, the first clinical trial for the use of CAR-T cell therapy to treat systemic lupus erythematosus in children was approved by the US Food and Drug Administration （FDA）. The trial was to take place at Seattle Children's Hospital in Washington, USA.
● In May 2024, Kite Pharma and Arcellx announced plans to begin Phase III of a clinical trial for multiple myeloma. The trial will investigate the effect of Anito-cel, a type of CAR-T cell therapy, in approximately 450 adults in Europe, North America, and other parts of the world.
● In April 2024, Bristol-Myers Squibb, a renowned pharmaceutical company, announced that it had signed a manufacturing agreement for CAR-T cell therapy with Theraless, a US-based contract manufacturer. The deal was signed for USD 380 million and is expected to help Bristol expand its supply of CAR-T cells in Japan, the US, and many European countries.
Market Forecast and Future Outlook
The CAR-T cell therapy market is poised to experience exponential growth in the coming years, fueled by technological breakthroughs, a robust R&D pipeline, and expanding clinical indications. As manufacturing costs decrease and new treatments gain regulatory approval, CAR-T cell therapy aims to transform cancer treatment worldwide. The
full report can be found here - https://www.skyquestt.com/report/car-t-cell-therapy-market
配信元企業：SkyQuest Technology and Consulting Pvt. Ltd.
プレスリリース詳細へ
ドリームニューストップへ
The CAR-T cell therapy market size is valued at USD 3.62 billion in 2023 and is poised to grow from USD 4.75 billion in 2024 to USD 41.78 billion by 2032, at a CAGR of 31.23% during the forecast period （2025-2032）.
Get Free Sample Report Now - https://www.skyquestt.com/sample-request/car-t-cell-therapy-market
Key Drivers of CAR-T Cell Therapy Market
● Increasing Prevalence of Cancer Globally - Rising incidence of various cancers is driving the adoption of innovative immunotherapies like CAR T-Cell therapy.
● Advances in Gene Editing and Cell Engineering - Technological advancements are improving the efficacy and safety profile of CAR-T Cell therapy.
● Expanding Regulatory Approvals and Clinical Trials - Increasing FDA and EMA approvals, as well as clinical trials globally, are fueling market growth.
● Growing Investments by Biopharmaceutical Companies - Large pharmaceutical and biotechnology companies are investing in research and development of next-generation CAR-T-Cell products.Market SegmentationThe
global
CAR-T cell therapy market is segmented by product, target, indication, demographics, end user, and region.
● Based on product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other products.
● Based on target, the market is segmented into CD19, BCMA, and Other targets.
● Based on indication, the market is segmented into multiple myeloma, B-cell lymphoma, acute lymphoblastic leukemia, and other indications.
● Based on demographics, the market is segmented into adult and pediatric.
● Based on end user, the market is segmented into hospitals, specialty centers, and long-term care facilities.
● Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East &Africa.
Regional Insights
North America is projected to hold a dominant share in the global CAR-T cell therapy market. High investments in medical research and development and growing acceptance of cell therapy among patients are projected to aid the high market share in this region.
The United States is estimated to be the most favorable market for CAR-T cell therapy companies owing to the presence of major CAR-T cell therapy providers. The potential for high healthcare costs and increasing availability of reimbursement for CAR-T cell therapy will also create new opportunities for CAR-T cell therapy providers in the future.
The Asia Pacific region is anticipated to emerge as the fastest-expanding CAR-T cell therapy market in the world in the coming years. Rapid growth in patient population, rising healthcare expenditure, and increasing demand for new treatments are estimated to bolster the demand for CAR-T cell therapy in the region.
China, Japan, and India are expected to emerge as the most favorable markets for all CAR-T cell therapy companies globally. Also, the presence of multiple contract research organizations and ease of regulatory approval procedures will play a key role in driving the demand for CAR-T cell therapy in the Asia-Pacific region in the coming years.
Challenges and Future
OpportunitiesChallenges:
● High cost of CAR-T cell therapy limiting accessibility
● Complex manufacturing and logistical requirements
● Potential for severe side effects such as cytokine release syndromeOpportunities
:
● Development of off-the-shelf （allogeneic） CAR-T cell therapy
● Application in the treatment of solid tumours other than hematological cancers
● Integration with advanced gene editing technologies such as CRISPRTop
Players in the CAR-T Cell Therapy Market
● Novartis AG （Switzerland）
● Johnson &Johnson （USA）
● JW （Cayman） Therapeutics Ltd. （Cayman Islands）
● Immunoadoptive Cell Therapy Private Limited （Immunoact） （India）
● Carsgen Therapeutics Holdings Limited （China）
● IASO Biotherapeutics （China）
● Guangzhou Bio-Gene Technology Co., Ltd （Hejing Group Co., Ltd） （China）
● Cartesian Therapeutics, Inc. （USA）
● Autolus Therapeutics （UK）
● Allogene Therapeutics （USA）
● Crispr Therapeutics （Switzerland）
● Ugen （USA）
● Sangamo Therapeutics, Inc. （USA）
● Bluebird Bio, Inc. （USA）
● TCR2 Therapeutics Inc. （USA）
● Genocea Biosciences, Inc. （USA）
● Blairex Laboratories, Inc. （USA）
● Medigene AG （Germany）
● Athenex, Inc. （USA）
● Zymeworks Inc. （Canada）
● Regenxbio Inc. （USA）
Recent Developments
● In April 2024, the first clinical trial for the use of CAR-T cell therapy to treat systemic lupus erythematosus in children was approved by the US Food and Drug Administration （FDA）. The trial was to take place at Seattle Children's Hospital in Washington, USA.
● In May 2024, Kite Pharma and Arcellx announced plans to begin Phase III of a clinical trial for multiple myeloma. The trial will investigate the effect of Anito-cel, a type of CAR-T cell therapy, in approximately 450 adults in Europe, North America, and other parts of the world.
● In April 2024, Bristol-Myers Squibb, a renowned pharmaceutical company, announced that it had signed a manufacturing agreement for CAR-T cell therapy with Theraless, a US-based contract manufacturer. The deal was signed for USD 380 million and is expected to help Bristol expand its supply of CAR-T cells in Japan, the US, and many European countries.
Market Forecast and Future Outlook
The CAR-T cell therapy market is poised to experience exponential growth in the coming years, fueled by technological breakthroughs, a robust R&D pipeline, and expanding clinical indications. As manufacturing costs decrease and new treatments gain regulatory approval, CAR-T cell therapy aims to transform cancer treatment worldwide. The
full report can be found here - https://www.skyquestt.com/report/car-t-cell-therapy-market
配信元企業：SkyQuest Technology and Consulting Pvt. Ltd.
プレスリリース詳細へ
ドリームニューストップへ
情報提供元： Dream News